Logo image of OCS

OCULIS HOLDING AG (OCS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OCS - CH1242303498 - Common Stock

23.84 USD
+0.18 (+0.76%)
Last: 1/15/2026, 8:03:48 PM
23.84 USD
0 (0%)
After Hours: 1/15/2026, 8:03:48 PM
Fundamental Rating

2

Taking everything into account, OCS scores 2 out of 10 in our fundamental rating. OCS was compared to 190 industry peers in the Pharmaceuticals industry. While OCS seems to be doing ok healthwise, there are quite some concerns on its profitability. OCS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • OCS had negative earnings in the past year.
  • OCS had a negative operating cash flow in the past year.
  • OCS had negative earnings in each of the past 5 years.
  • In the past 5 years OCS always reported negative operating cash flow.
OCS Yearly Net Income VS EBIT VS OCF VS FCFOCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of OCS (-62.02%) is worse than 66.84% of its industry peers.
  • OCS has a Return On Equity of -79.71%. This is comparable to the rest of the industry: OCS outperforms 41.05% of its industry peers.
Industry RankSector Rank
ROA -62.02%
ROE -79.71%
ROIC N/A
ROA(3y)-84.45%
ROA(5y)-75.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCS Yearly ROA, ROE, ROICOCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • OCS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCS Yearly Profit, Operating, Gross MarginsOCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for OCS has been increased compared to 1 year ago.
  • OCS has a worse debt/assets ratio than last year.
OCS Yearly Shares OutstandingOCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
OCS Yearly Total Debt VS Total AssetsOCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 18.19 indicates that OCS is not in any danger for bankruptcy at the moment.
  • OCS has a better Altman-Z score (18.19) than 86.32% of its industry peers.
  • OCS has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • OCS's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. OCS outperforms 55.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 18.19
ROIC/WACCN/A
WACCN/A
OCS Yearly LT Debt VS Equity VS FCFOCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • OCS has a Current Ratio of 4.47. This indicates that OCS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of OCS (4.47) is better than 62.11% of its industry peers.
  • A Quick Ratio of 4.47 indicates that OCS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 4.47, OCS is in the better half of the industry, outperforming 64.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47
OCS Yearly Current Assets VS Current LiabilitesOCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

  • OCS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.60%.
EPS 1Y (TTM)-22.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.5%

3.2 Future

  • OCS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.87% yearly.
  • Based on estimates for the next years, OCS will show a very strong growth in Revenue. The Revenue will grow by 181.98% on average per year.
EPS Next Y10.85%
EPS Next 2Y4.82%
EPS Next 3Y0.36%
EPS Next 5Y5.87%
Revenue Next Year-17.65%
Revenue Next 2Y155.24%
Revenue Next 3Y301.35%
Revenue Next 5Y181.98%

3.3 Evolution

OCS Yearly Revenue VS EstimatesOCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
OCS Yearly EPS VS EstimatesOCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • OCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCS Price Earnings VS Forward Price EarningsOCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCS Per share dataOCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.82%
EPS Next 3Y0.36%

More info and screens

0

5. Dividend

5.1 Amount

  • OCS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

OCULIS HOLDING AG

NASDAQ:OCS (1/15/2026, 8:03:48 PM)

After market: 23.84 0 (0%)

23.84

+0.18 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)03-03
Inst Owners29.24%
Inst Owner ChangeN/A
Ins Owners2.75%
Ins Owner ChangeN/A
Market Cap1.38B
Revenue(TTM)N/A
Net Income(TTM)-104.10M
Analysts86.67
Price Target44.88 (88.26%)
Short Float %0.2%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.37%
Min EPS beat(2)-4.51%
Max EPS beat(2)25.25%
EPS beat(4)1
Avg EPS beat(4)-21.81%
Min EPS beat(4)-56.2%
Max EPS beat(4)25.25%
EPS beat(8)3
Avg EPS beat(8)-13.47%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)30.83%
Min Revenue beat(2)24.83%
Max Revenue beat(2)36.82%
Revenue beat(4)3
Avg Revenue beat(4)-2.05%
Min Revenue beat(4)-98.55%
Max Revenue beat(4)36.82%
Revenue beat(8)3
Avg Revenue beat(8)-6.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.25%
PT rev (3m)20%
EPS NQ rev (1m)1.82%
EPS NQ rev (3m)-5.5%
EPS NY rev (1m)0.18%
EPS NY rev (3m)1.08%
Revenue NQ rev (1m)-14.29%
Revenue NQ rev (3m)-37.19%
Revenue NY rev (1m)-15.16%
Revenue NY rev (3m)-16.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.46
P/tB 9.41
EV/EBITDA N/A
EPS(TTM)-2.71
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS2.82
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -62.02%
ROE -79.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.45%
ROA(5y)-75.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 275.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z 18.19
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)418.9%
Cap/Depr(5y)255.58%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y10.85%
EPS Next 2Y4.82%
EPS Next 3Y0.36%
EPS Next 5Y5.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12.5%
Revenue Next Year-17.65%
Revenue Next 2Y155.24%
Revenue Next 3Y301.35%
Revenue Next 5Y181.98%
EBIT growth 1Y-14.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.84%
EBIT Next 3Y-12.86%
EBIT Next 5Y6.68%
FCF growth 1Y-25.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.63%
OCF growth 3YN/A
OCF growth 5YN/A

OCULIS HOLDING AG / OCS FAQ

Can you provide the ChartMill fundamental rating for OCULIS HOLDING AG?

ChartMill assigns a fundamental rating of 2 / 10 to OCS.


Can you provide the valuation status for OCULIS HOLDING AG?

ChartMill assigns a valuation rating of 0 / 10 to OCULIS HOLDING AG (OCS). This can be considered as Overvalued.


Can you provide the profitability details for OCULIS HOLDING AG?

OCULIS HOLDING AG (OCS) has a profitability rating of 0 / 10.


What is the expected EPS growth for OCULIS HOLDING AG (OCS) stock?

The Earnings per Share (EPS) of OCULIS HOLDING AG (OCS) is expected to grow by 10.85% in the next year.